1. Aggressive anticancer treatment in the last 2 weeks of lifeNena Golob, Teja Oblak, Luka Čavka, Maša Kušar, Boštjan Šeruga, 2024, original scientific article Abstract: Background: There is a concern that terminally ill cancer patients may be aggressively treated due to the rapidly growing possibilities of anticancer treatment. The aim of this study was to evaluate the use of anticancer treatment at the end of life (EoL). Materials and methods: This retrospective study included adult patients with advanced solid cancers who were treated at the Institute of Oncology Ljubljana and died of cancer between January 2015 and December 2019. A multiple logistic regression model was used to assess an association between the aggressiveness of anticancer treatment (i.e. systemic therapy, radiotherapy and surgery) in the last 2 weeks of life and year of death, age at death, sex, prognosis of cancer and enrolment into the specialist palliative care (SPC). Results: We included 1736 patients in our analysis. Overall, 13.7% of patients were enrolled into the SPC and 14.4% received anticancer treatment in the last 2 weeks of life. The odds of receiving anticancer treatment significantly increased over time [odds ratio (OR) 1.15, 95% confidence interval (CI) 1.04-1.27]. There was an increased use of novel systemic therapy (e.g. small-molecule targeted therapy and immunotherapy) at the EoL. Older patients had significantly lower odds to receive anticancer treatment in the last 2 weeks of life as compared to younger patients (OR 0.96, 95% CI 0.95-0.98). As compared to patients receiving only a standard oncology care, those also enrolled into the SPC had significantly lower odds for anticancer treatment in the last 2 weeks of life (OR 0.22, 95% CI 0.12-0.43). Conclusions: Terminally ill cancer patients have increased odds for receiving anticancer treatment, especially novel systemic therapies, in the last 2 weeks of life. Younger patients and those not enrolled into the SPC are at particular risk for anticancer treatment at the EoL Keywords: systemic therapy, aggressive treatment, anticancer drugs, palliative care Published in DiRROS: 18.04.2024; Views: 22; Downloads: 13 Full text (335,97 KB) This document has many files! More... |
2. Osteoblastic bone metastases from renal cell carcinomaVladka Salapura, Irena Preložnik Zupan, Boštjan Šeruga, Gorana Gašljević, Pavel Kavčič, 2014, original scientific article Abstract: Background. RCC accounts for only 2-3% of all cancers. Due to its non-specific symptoms disease is often diagnosed in advanced stage. Disseminated RCC frequently produces bone metastases that are almost always highly destructive, hyper vascularized and purely osteolytic. Case report. In this article we describe a case of a 71-year old male patient with disseminated osteoblastic bone metastases from renal cell carcinoma (RCC), and present a short review of published literature reporting cases of osteoblastic bone metastases from RCC. Our patient presented with thoracic pain aggravated by movement. He was diagnosed with predominantly osteoblastic bone metastases in the skeleton of thoracic and lumbar vertebra along with metastases in iliac bones, ribs, humerus and clavicles. Initially, origin of bone metastases was unknown, but later a small tumor in patients right kidney was identified. Microscopic evaluation of the open bone biopsy showed clear cell RCC with sarcomatoid differentiation. Conclusions. Although, due to its rarity, RCC is not included in the primary differential diagnosis in patients with osteoblastic metastases, such rare cases suggest that RCC may be considered in the diagnosis when there no other primary tumor is found. Published in DiRROS: 11.04.2024; Views: 66; Downloads: 8 Full text (758,62 KB) |
3. |
4. Paratesticular adenocarcinoma : unusual presentation of metastasis of pancreatic cancerJanja Ocvirk, Boštjan Šeruga, 2007, short scientific article Abstract: Background. Metastatic paratesticular adenocarcinoma from the pancreatic cancer is very rare. To our knowledge, there are less than 20 cases published in the literature. Case report. We experienced a case of paratesticular adenocarcinoma from the primary pancreatic cancer. A 42-year-old man was presented with locoregionally advanced carcinoma of the tail of the pancreas with intraoperatively found liver metastases and with a tumour in the right hemi-scrotum. Ultrasound of the scrotum revealed a paratesticular tumour. A fine needle aspiration biopsy (FNAB) confirmed a poorly differentiated adenocarcinoma and it was in concordance with the diagnosis of the primary tumour. The patient started treatment with chemotherapy with gemcitabine. Unfortunately, he progressed one month later and the treatment was discontinued. Conclusions. Outcome in the adenocarcinoma of the pancreas is dismal. The only possible treatment option for metastatic disease is systemic therapy but the results are disappointing, as in the present case. Published in DiRROS: 19.02.2024; Views: 96; Downloads: 29 Full text (78,71 KB) |
5. Preoperative concomitant chemoradiotherapy in esophageal cancerBoštjan Šeruga, Mihael Sok, Janez Eržen, Jože Jerman, Boris Jančar, Branko Zakotnik, 2006, original scientific article Abstract: Background. Currently primary treatment options for esophageal cancer are surgery only or concomitant chemoradiotherapy (CRT) and the long-term survivalof patients with locally advanced disease is rare. Preoperative concomitant CRT seems to be beneficial, mostly in patients who achieve a complete pathologic response (pCR) after CRT. In this retrospective analysis the efficiency and toxicity of preoperative CRT in patients with locally advanced esophageal cancer was analysed as well as the influence of pCR on thesuraival. Patients and metkods From 1996 to 2002 41 patients with locoregionally confined esophageal cancerwere treated with cisplatin 75 mgžm2 and 5-FU 1000 mgžm2 as 4 day contonuous infusion starting on days 1. and 22. with concorrtitant radiotherapy 4500 cGy, 200-300 cGyžday. Esophagectomy followed 4-5 weeks after radiotherapy. After the surgery patients were followed-up regularly at 3-6 months intervals. Results. The pCR was achieved in 26.8% of patients. The overall median survival time was 18 months for all patients, 21.2 months for patients who achieved pCR and 16 months in those with residual disease (p= 0,79). Postoperative mortality rate was 22%. The median dose intensity for cisplatin was 92% and for 5-FU 71.5 of the planned dose. Disease recurred most often locoregionally (31.7%) and the overall recurrence rate was 43.9. Conclusion. Modern radiation techniques and the adequate dose intensity could further improve the locoregional control. The selection of patients without comorbid conditions and without already present distant metastases is essential for this combined treatment approach. Published in DiRROS: 15.02.2024; Views: 123; Downloads: 33 Full text (123,83 KB) |
6. |
7. Napotki za premagovanje neželenih učinkov sistemskega zdravljenja raka : kaj morate vedeti?Simona Borštnar, Boštjan Šeruga, Marjana Bernot, Marika Horvat, Barbara Jezeršek Novaković, Denis Mlakar-Mastnak, Janja Ocvirk, Samo Rožman, Monika Sonc, Snežana Umičević, Metka Zajc, Branko Zakotnik, 2023, dictionary, encyclopaedia, lexicon, manual, atlas, map Keywords: onkologija, bolniki, nasveti Published in DiRROS: 22.11.2023; Views: 312; Downloads: 128 Full text (798,13 KB) |
8. Prihodnost zdravljenja raka prostateBoštjan Šeruga, 2023, published scientific conference contribution Abstract: V zadnjem desetletju je bil dosežen velik napredek v zdravljenju raka prostate. Tudi v naslednjem desetletju si obetamo podoben ali še večji napredek. Veliko obetajo kombinacije zdravil, ki jih danes v praksi že uporabljamo, in nova protirakava zdravila. Pri raku prostate ostaja neizkoriščen potencial imunoterapije, ki jo bo v bodoče potrebno še nadgraditi. Hitrejši napredek v zdravljenju raka prostate bodo omogočili sodobni dizajni kliničnih raziskav. Keywords: rak prostate, onkološko zdravljenje, sistemsko zdravljenje Published in DiRROS: 03.02.2023; Views: 392; Downloads: 113 Full text (132,04 KB) |
9. |
10. Pomen PIK3CA aktivirajočih mutacij za izid bolezni pri bolnicah z invazivnim lobularnim karcinomom dojke, zdravljenih z dopolnilno endokrino terapijoDomen Ribnikar, Valentina Jerič Horvat, Ivica Ratoša, Zachary Veitch, Biljana Grčar-Kuzmanov, Srdjan Novaković, Erik Langerholc, Maja Pohar Perme, Eitan Amir, Boštjan Šeruga, 2022, published professional conference contribution abstract Keywords: onkologija, rak dojke, kemoterapija Published in DiRROS: 27.01.2023; Views: 405; Downloads: 110 Full text (46,13 KB) |